Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

NCT03504982 PHASE1 COMPLETED

The primary objective of this study was to investigate whether there is a clinically meaningful effect on QTc change from baseline relative to placebo after administration of 10 mg at steady state in patients with stable CAD (coronary artery disease).

Details

Lead sponsor	Bayer
Phase	PHASE1
Status	COMPLETED
Enrolment	74
Start date	Thu May 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Coronary Artery Disease

Interventions

• Vericiguat (BAY1021189)
• Moxifloxacin
• Placebo

Countries

Netherlands, Germany, Moldova